Gerhard Hamilton

Medical University of Vienna Austria

Dr. Gerhard Hamilton studied biochemistry at the University of Vienna, Austria. After finishing his doctoral thesis on Natural Killer cells he got a position in the research laboratories of the Department of Surgery at the University Medical School of Vienna and obtained the degree of associate professor in 1996. His scientific publications comprise the fields of organ transplantation, burn care, sepsis and oncology. Later on his research projects have focused on in vitro characterization of anticancer compounds such as novel platinum-based agents and titanocenes and respective mechanisms of drug resistance associated with cellular expression of relevant transporter proteins as well as changes in global gene expression. One special topic has been the investigation of diagnostic tests based on cytokeratin fragments in prostate and colorectal cancer patients revealing the applicability of the assays to prove residual tumor load. In addition, Dr. Hamilton has been the scientific coordinator of the “Ludwig Boltzmann Cluster of Translational Oncology” since 2006.

Gerhard Hamilton

1books edited

2chapters authored

Latest work with IntechOpen by Gerhard Hamilton

The first chapters of the volume "Cytokeratins - Tools in Oncology" discuss multiple functions of cytokeratins in organization of the intermediary filaments in normal intestine and liver as well as microfold L cells and the usability of cytokeratins 7, 8 and 20 in tumor diagnosis in detail. Epithelial to mesenchymal transition as a mechanism important in pathogenesis is touched in another chapter, followed by several articles dealing with the role of cytokeratins for detection of disseminated tumor cells and as response markers during chemotherapy. This book is therefore destined to all cancer researchers and therapists who want to understand the diagnostic application of cytokeratins in histology and, especially, the use of anti-cytokeratin antibodies to identify viable residual tumor cells accounting for a higher risk of tumor recurrence or cancer cells responding to chemotherapy, respectively.

Go to the book